Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Results of a phase two clinical trial show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three–year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome–positive acute lymphoblastic leukemia.

   

Today in Popular Press...keeping you current

How nutrition affects healthy aging
EurekAlert, 12/07/09

Mayo Clinic and collaborators find vitamin D levels associated with survival in lymphoma patients
EurekAlert, 12/07/09

Multiple myeloma patients experience high response rate with new 3-drug combination
EurekAlert, 12/07/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address